What were the key takeaways from Absci's earnings call?

What is Absci's gross profit margin?

What is the revenue and EPS growth rate for Absci year over year?

What factors drove the changes in Absci's revenue and profit?

Did Absci beat or miss consensus estimates last quarter?

What guidance did Absci's management provide for the next earnings period?

What is Absci's latest dividend and current dividend yield?

What does Absci do and what are its main business segments?

- **ABS-201 Clinical Momentum**: Dosed first 3 SAD cohorts in AGA trial with favorable safety; 13-week POC data expected H2 2026. Expanded into endometriosis with potential for disease-modifying therapy. 
- **AI Platform Differentiation**: Published first de novo antibody design with 0 prior epitopes; Origin-1 generates <100 designs per target vs. industry standards. 
- **Financial Strength**: $144M cash runway into 2028; R&D expenses up 37% to $25.3M to fund clinical trials. 
- **Market Opportunity**: $25B+ AGA addressable market; $10B+ endometriosis opportunity with no FDA-approved disease-modifying therapies.

**【CEO Summary Section】**
 Absci dosed the first 3 SAD cohorts in its phase I/IIa HEADLINE trial for ABS-201 in AGA, with favorable safety data and emerging PK support for the dosing regimen. The company expanded into endometriosis as a second indication, targeting a $25B+ AGA market and a $10B+ endometriosis opportunity. ABS-201's extended half-life (3-4x longer than competitors) enables 2-3 administrations for multi-year hair regrowth. Key clinical milestones include 13-week interim data in H2 2026 and 26-week data in early 2027. The company also published the first demonstration of de novo antibody design with 0 prior epitopes, showcasing its Origin-1 AI platform's ability to generate full-length antibodies in <100 designs per target.

**【CMO Clinical Update】**
 Ransi Somaratne, CMO, detailed the HEADLINE trial design: a randomized, double-blind, placebo-controlled study with SAD (4 IV dose groups) and MAD (3 SC dose groups) phases. Primary endpoints: safety, tolerability; secondary: PK, PD, hair metrics. The trial enrolls 227 healthy volunteers with AGA, with 13-week interim and 26-week full POC readouts. ABS-201's mechanism inhibits local prolactin receptor signaling, preserving the stem cell niche and enabling follicular reconversion. The company is engaging with FDA on an expedited path to phase III, potentially leveraging SAD data to initiate endometriosis trials in Q4 2026. Preclinical data suggest ABS-201 may address both pain and lesion growth in endometriosis, targeting a non-sex hormone pathway with no FDA-approved disease-modifying therapies.

**【CFO Financial Commentary】**
 - Q4 2025 revenue: $0.7M (partnered programs); R&D: $25.3M (vs. $18.4M prior year), driven by ABS-201 and ABS-101 clinical costs. SG&A: $8.6M (flat vs. prior year). 
 - Cash position: $144.3M (vs. $152.5M prior quarter), supporting operations into H1 2028. 
 - $5.1M gain on contingent consideration settlement; net proceeds $8.7M. 
 - Balance sheet sufficient for upcoming catalysts: safety/PK data (H1 2026), 13-week POC (H2 2026), and endometriosis trial initiation (Q4 2026).

**【Q&A Highlights】**
 - **Target Product Profile**: TPP assumes 30-40 hairs/cm² regrowth (comparable to high-dose minoxidil) with 2-3-year durability. 87% of men and 69% of women surveyed said they'd "extremely likely" seek ABS-201 if available. 
 - **Safety**: No on-target/off-target safety signals in SAD cohorts; PK aligns with preclinical models. 
 - **Partnerships**: Actively negotiating platform deals with pharma; prioritizing programs with low competition and high R&D efficiency (e.g., oncology assets ABS-301/501). 
 - **Market Competition**: AGA TPP differentiated by convenience (2-3 injections vs. daily topical); endometriosis addresses $10B+ underserved market with no disease-modifying therapies.

Absci Corp (ABSI) Q4 2025 Earnings Call Transcript

- **Strategic Pivot**: ABS-201 prioritized for AGA and endometriosis, with phase I/IIa trial starting in December 2025 and endometriosis phase II in Q4 2026.
- **Financial Strength**: $152.5M cash runway into H1 2028; expect pharma partnerships to enhance capital efficiency.
- **Pipeline Streamlining**: ABS-101 to be partnered; ABS-301/501 pre-clinical collaborations in progress.
- **Mechanism Validation**: Ex-vivo data confirms ABS-201’s ability to drive hair regrowth and reduce stem cell apoptosis.

**【CEO Summary Section】**
- **ABS-101 Update**: Interim phase I results showed extended half-life vs first-gen competitors but fell short of next-gen. Decision made to seek a partner for ABS-101 and halt internal phase II development.
- **ABS-201 Expansion**: 
  - AGA trial (phase I/IIa) to begin in December 2025 with interim readout in H2 2026.
  - New indication in endometriosis with phase II trial planned for Q4 2026, targeting interim readout in H2 2027.
  - Ex-vivo data shows ABS-201 transitions hair follicles to anagen phase and reduces stem cell apoptosis.
- **Pipeline Strategy**: Prioritize ABS-201 for AGA and endometriosis due to multi-billion dollar market potential. ABS-301 and ABS-501 to be partnered pre-clinically.

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: 
  - Revenue: $400k
  - R&D Expenses: $19.2M (vs $18M prior year)
  - Cash Reserves: $152.5M (vs $117.5M prior quarter)
- **Funding Outlook**: Current cash sufficient to fund operations into H1 2028. Expect non-dilutive cash inflows from new pharma partnerships.
- **Partnership Progress**: Anticipate signing 1+ drug creation partnerships by year-end, including large pharma collaboration.

**【Q&A Key Highlights】**
- **ABS-101 Partnering**: Discussions ongoing with large/mid-cap pharma for first-in-class indications outside IBD. Data sharing with partners planned in coming weeks.
- **ABS-201 Trial Design**: 
  - AGA trial (phase I/IIa): 227 pts, SAD/SC MAD arms. Efficacy metrics include terminal hair count at 13 weeks.
  - Endometriosis trial (phase II): Leverage AGA safety data. Focus on pain reduction and lesion suppression.
- **Competitive Landscape**: Endometriosis space less crowded than IBD. HMI-115 phase II data de-risked prolactin receptor mechanism.
- **Ex-Vivo Data**: ABS-201 upregulated stem cell markers in human scalp biopsies, validating mechanism in AGA.

Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript

- **Clinical Milestones**: ABS-101 Phase I interim data Q4 2025; ABS-201 Phase I/IIa starts early 2026 with potential 2026 efficacy readout.
- **Financial Strength**: $181.5M cash post-Q2 raise, supporting operations into 2028.
- **Strategic Partnerships**: $650M+ potential from Almirall collaboration; 1+ large pharma deals expected in 2025.
- **AI Differentiation**: Success in drug creation for ion channels (Almirall) and novel antibody designs (ABS-501).

**【CEO Opening Remarks】**
- Initiated Phase I clinical trial for ABS-101 (anti-TL1A antibody) in May 2025, targeting interim results later this year. ABS-101's bispecific variant with a novel arm has strong partner interest.
- ABS-201 (anti-prolactin receptor for androgenetic alopecia) advancing to Phase I/IIa trial in early 2026, with potential interim efficacy data in late 2026. Program designed for subcutaneous dosing every 6 months.
- Expanded pipeline includes ABS-301 (immuno-oncology) and ABS-501 (anti-HER2), with early-stage programs targeting GPCRs and ion channels.
- AMD's $20M strategic investment reflects confidence in AI-driven drug creation platform, supporting collaboration on antibody design workloads.

**【CFO Financial Update】**
- Q2 2025 revenue: $600,000; R&D expenses: $20.5M (vs. $15.3M YoY), driven by clinical advancement and personnel costs. SG&A: $8.5M (vs. $9.3M YoY), down due to stock comp reduction.
- Post-quarter, raised $64M via public offering and ATM, bringing total cash to $181.5M. This provides runway into H1 2028, with potential upside from new partnerships or asset sales.
- Almirall collaboration milestone: $650M+ potential payments across two programs targeting difficult-to-drug ion channels.

**【Q&A Highlights】**
- **ABS-101 Clinical Design**: 40 healthy volunteers in Phase I, with PK/PD and immunogenicity data expected Q4 2025. Targeting quarterly dosing based on half-life.
- **ABS-201 Development Path**: Subcutaneous formulation for 6-month dosing cycle; Phase I/IIa will include female patients to explore endometriosis indication alongside alopecia.
- **Partnership Strategy**: Seeking 1+ large pharma deals in 2025 for platform access or asset licensing. ABS-301/501 likely partnered at preclinical stage, while ABS-201 retained for internal development.
- **Competitive AI Platform**: Focus on de novo antibody design for GPCRs/ion channels, with Almirall collaboration demonstrating success in challenging targets.
- **Capital Allocation**: Prioritize clinical readouts (ABS-101 interim, ABS-201 Phase I/IIa) and partnership discussions, with $181.5M cash to support 3+ years of operations.

Absci Corporation (ABSI) Q2 2025 Earnings Call Transcript

- **Clinical Breakthrough**: ABS-101 enters Phase I, with interim data expected late 2025 to validate safety and target engagement.
- **Hair Regrowth Innovation**: ABS-201 shows potential for 8-12 week dosing, targeting 80M+ patients with unmet needs.
- **AI-Driven Differentiation**: FDA's AI focus aligns with Absci's naturalness model, reducing immunogenicity and enhancing therapeutic design.
- **Financial Resilience**: $134M cash runway supports operations into 2027, with potential upside from partnerships and asset sales.
- **Strategic Growth**: Bispecific combo strategy and internal program retention (ABS-201) balance collaboration and value capture.


**【CEO Summary Section】**
- **ABS-101 Clinical Milestone**: Initiated Phase I trial for anti-TL1A antibody, targeting safety, tolerability, and PK/PD in 40 healthy volunteers. Interim data expected late 2025.
- **ABS-201 Hair Regrowth Program**: Nominated development candidate with extended half-life (8-12 weeks dosing) and >90% bioavailability in NHPs. Phase I trial anticipated Q1 2026.
- **AI Platform Strength**: Leveraged generative AI to design novel therapeutics, including bispecific antibody combining TL1A with a novel target. FDA's push for AI-driven safety models aligns with Absci's naturalness model, reducing immunogenicity risks.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: Revenue $1.2M; R&D expenses $16.4M (vs. $12.2M YoY), driven by internal program advancement. Cash balance $134M, supporting operations into H1 2027.
- **Partnership Outlook**: Anticipating 1+ new collaborations with large pharma, including potential asset transactions (e.g., ABS-101). Nondilutive cash inflows could accelerate timeline.

**【Q&A Key Points】**
- **ABS-101 Combo Strategy**: Developing bispecific with novel target for autoimmune diseases, alongside monotherapy. Both paths have strong partner interest.
- **ABS-201 Commercialization**: Planning for provider-administered launch, with potential self-administration in later stages. Targeting broad patient population (~80M U.S. adults).
- **FDA Animal Testing Shift**: AI models for toxicity prediction (e.g., naturalness score) position Absci to lead in reduced-animal-testing era, enhancing partner appeal.

**【Cost and Risk Management】**
- **Flexible Cost Structure**: AI platform efficiency enables resource reallocation. Current R&D spend focused on high-value internal programs (ABS-201, ABS-301) with clear clinical paths.
- **Partnership Economics**: Expect improved terms as platform validation (e.g., HIV Caldera case study) and AI differentiation drive pharma interest.


Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript

- **Breakthrough Antibody Design**: De novo AI platform creates first-in-class HIV antibodies targeting undruggable epitopes, with potential for universal neutralization.
- **Hair Loss Innovation**: ABS-201 shows superior efficacy vs. minoxidil, with Phase I trial in early 2025 targeting 80M U.S. patients with androgenic alopecia.
- **Financial Strength**: $112M cash on hand, $40M raised in Q1 2025, supporting clinical trials for ABS-101 and ABS-201 through 2026.
- **Strategic Shift**: Moving from partner volume to high-value co-development deals, with 1+ large pharma collaborations expected in 2025.
- **AI-Driven Efficiency**: AMD partnership reduces R&D timelines by 30%, enabling faster model iteration and target validation.


**【CEO Summary Section】**
- **2024 Year Highlights**: Added 4 new partners, advanced internal programs (ABS-201, ABS-101), and showcased AI platform breakthroughs in antibody design. ABS-201 targets androgenic alopecia with preclinical data showing superior efficacy vs. minoxidil, with Phase I expected in early 2025.
- **AI Platform Progress**: Achieved de novo design of antibodies targeting HIV's Caldera region, a previously undruggable epitope. Collaboration with AMD provides optimized compute solutions, reducing R&D timelines by 30%.
- **Pipeline Momentum**: ABS-101 (anti-TL1A) Phase I trial to begin in H1 2025 with interim readout in H2. ABS-301 and ABS-501 show promising preclinical efficacy in immuno-oncology and HER2+ cancers.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: Revenue $0.7M, R&D expenses $18.4M (vs. $12.3M prior year), driven by internal program advancement. Full-year cash burn $72M, ending with $112.4M in cash. Raised $40M in Q1 2025 via AMD equity investment and ATM facility.
- **Partnership Strategy Shift**: Moving from volume-based partner count to high-value co-development deals (e.g., large pharma collaboration). 1+ new partnerships expected in 2025, focusing on first-in-class therapeutics.
- **Cash Outlook**: Current cash sufficient to fund operations into H1 2027. Accelerating ABS-201 development with potential interim efficacy readout in 2026.

**【Q&A Key Takeaways】**
- **ABS-101 Clinical Design**: SAD/MAD studies to include soluble TL1A elevation and safety metrics. Interim readout in H2 2025 will assess target engagement and tolerability.
- **Large Pharma Partnerships**: Discussions center on de novo design capabilities for undruggable targets (e.g., ion channels, GPCRs). Potential bispecific combining TL1A with novel target to address unmet needs in IBD/UC.
- **HIV Program Progress**: Collaboration with Caltech and Gates Foundation advancing preclinical studies, with clinical plans to be announced post-in vivo data.
- **AI Model Iteration**: Lab-in-the-loop process enables 6-week model updates, improving accuracy and generalizability. New data from partnered programs rapidly integrated to enhance design efficiency.


Actual	-2.39	-0.33	-0.28	-0.33	-0.32	-0.3	-0.21	-0.26	-0.45	-0.24	-0.25	-0.22	-0.22	-0.24	-0.25	-0.21	-0.24	-0.2	-0.2
Forecast	-0.1714	-0.202	-0.247	-0.2883	-0.3122	-0.283	-0.2515	-0.232	-0.238	-0.23	-0.2125	-0.2117	-0.1814	-0.1941	-0.2237	-0.2237	-0.2086	-0.205	-0.1778
Surprise	-1294.40%	-63.37%	-13.36%	-14.46%	-2.50%	-6.01%	+16.50%	-12.07%	-89.08%	-4.35%	-17.65%	-3.92%	-21.28%	-23.65%	-11.76%	+6.12%	-15.05%	+2.44%	-12.49%

ABSI

ABSI fundamentals

ABSI Q4 2025 Earnings

Earnings Call

You can ask Aime

ABSI

ABSI fundamentals

ABSI Q4 2025 Earnings

Earnings Call

ABSI Earnings Call Summary for Q4/20254:30 PM on Mar 24, 2026

ABSI Earnings Call Summary for Q3/20254:30 PM on Nov 12, 2025

ABSI Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

ABSI Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

ABSI Earnings Call Summary for Q4/20244:30 PM on Mar 18, 2025

You can ask Aime